Makes health insurance public

PARIS, Wednesday, June 22, 2022 – The National Health Insurance Fund (CNAM) yesterday unveiled an interactive map called Data pathologies that collects data from the 1.5 billion care papers produced annually.

This tool provides the general public with a set of data (data in news language) on 57 diseases, chronic treatments and episodes of care. It also makes it possible to visualize the progression of infection and the cost of these diseases.

This designation relates to a total of €168 billion in annual health spending in 2020 for 66.3 million people.

More than 3 million French people follow cancer

For each of these disease groups, the site provides access to the number of patients involved, breakdown by gender, and total expenditure, development and expenditure per patient and per year.

We note, for example, that 8,421,360 Social Security beneficiaries benefited from vascular risk coverage in 2020, and that 3,371,090 were followed for cancer and 2,769,590 for psychiatric disease, at an annual cost per patient, respectively, 669 euros, 6,290 euros and 5,926 euros.

Unfortunately, not everything is traceable Damien Verger, Director of Strategy, Studies and Statistics at CNAM, during the press presentation. “If you go to your GP and do a consultation for influenza syndrome, gastroenterology, we just see the consultation appear in our information system. It’s not the prescription that will help us identify the pathology. That’s one of the limits,” he explains.

heavy trends

Health insurance has learned several lessons from analyzing this data between 2015 and 2020 and observations Big changes.

Over five years, spending has increased by more than 15 billion euros, with a slowdown in 2020 linked to the health crisis. “We see a focus of health spending around people with chronic diseases,” Thomas Vatom, CNAM’s Managing Director announced. Of the 168 billion euros spent, 104 billion are related to these diseases, i.e. “Two thirds of expenditures” For just over a third of policy holders (4,300 euros on average).

Perhaps the most notable example is oncology, where spending has increased sharply since 2015. “The average cost of treating active cancers has increased by 18.2% in 5 years,” said Thomas Phantom.. For lung cancer, for example, the cost of annual treatment per patient, within 5 years, increased from 16,900 euros to 25,300 euros on average (+50%).

Covid brand

“The main balances in terms of diseases remained the same in 2020, but for certain diseases we could have major disruptions,” Dr. Aiden Tajhamadi, Deputy Director of Strategy, Studies and Statistics, explained.

The fund identified nearly 200,000 patients who remained in hospital due to Covid-19, of whom 42,000 were in critical care. In total, Covid represented a total spending of 1.6 billion euros, of which 90% is for hospitalization. This represents a cost of €7,800 per patient.

Occasional hospitalizations have also been adjusted due to the health crisis. This relates to specially scheduled surgeries. Thus their number decreased by 1.2 million patients with a decrease in total spending by 4 billion euros (-10.6%). On the other hand, average per capita spending increased by 2.6%.
“This proves that perhaps the heaviest patients are the ones who have had these treatments.” Advanced Dr. Aiden Taj Hammadi.

Covid will also interfere with cardiovascular disease and acute heart failure attacks.

These episodes decreased by -10.5% in 2020, approximately 21,000 fewer patients. This can be explained in several ways. The first is that heart failure is a risk factor for severe Covid-19. So we have a number of patients for whom Covid was “in competition” with heart failure. The latter was hospitalized due to Covid and had no compensation from heart failure. On the other hand, for a certain number of these patients, this could be explained by less management of these acute episodes.”

Other effects “not directly” Particularly highlighted was the increase in the delivery of psychotropic therapies: +2.3% of patients involved in 2020.

There is no doubt that data pathology will become a valuable tool for healthcare professionals and administrators in the coming years.


F h

#health #insurance #public

Leave a Comment

Your email address will not be published.